Sign up to receive Invitae financial information by email. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. All of the shares are being offered by Invitae. Factors that may cause such a difference include risks and uncertainties related to completion of the public offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the public offering. 6132, or by email at syndicate@svbleerink.com. Press Release reported 16 hours ago that Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than … This press release contains forward-looking statements within the Private Securities Litigation Reform Act of 1995, including statements that relate to the timing, size and completion of the proposed public offering, the grant to the underwriters of the option to purchase additional shares, and other information that is not historical information. All of the shares are being sold by Invitae. Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. SAN FRANCISCO, Jan. 21, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. Based on the insurance provided, the out-of-pocket cost estimate is . Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Email: ir@invitae.com. Our team is driven to make a difference for the patients we serve. Invitae currently intends to use the net proceeds from the offering for working capital and other general corporate purposes, including investing in its platform, oncology and reproductive product extensions and international expansion. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Invitae may also use a portion of the net proceeds from this offering to acquire or invest in complementary businesses, assets or technologies, although it has no present commitments or agreements to do so. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. pr@invitae.com. (628) 213-3283. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Invitae may also use a portion of the net proceeds from this offering to acquire or invest in complementary businesses, assets or technologies, although it has no present commitments or agreements to do so. SAN FRANCISCO, Jan. 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. For Invitae Laura D'Angelo 628.213.3283 pr@invitae.com For PacBio Media: Colin Sanford 203.918.4347 colin@bioscribe.com. Invitae Corporation (NYSE: NVTA) is the leading advanced medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. More information about the risks and uncertainties faced by Invitae is contained in the section captioned "Risk factors" in the preliminary prospectus supplement related to the public offering filed with the Securities and Exchange Commission. Invitae is dedicated to bringing genetic information into mainstream medicine to improve healthcare for billions of people. For more information, visit the company's website at invitae.com. Contact:Laura D'Angeloir@invitae.com(628) 213-3369, View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-announces-pricing-of-public-offering-of-common-stock-301212976.html, 1400 16th St. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the implications of the study results; and the benefits of genetic testing for men with prostate cancer and their … J.P. Morgan Securities LLC, Morgan Stanley, Cowen and Company, LLC and SVB Leerink LLC are acting as the book-running managers for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 6132, or by email at syndicate@svbleerink.com. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, … Confirm a diagnosis, provide a better understanding of prognosis, and direct medical management. For more information… In addition to offering a variety of genetic test options for consumers, the company also seeks to share test results freely, bringing comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Factors that may cause such a difference include risks and uncertainties related to completion of the public offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the public offering. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Invitae will report its full financial results and other metrics during its … Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. A copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY, 10014, Attention: Prospectus Department; from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com, or by telephone at (833) 297-2926; or from SVB Leerink LLC, One Federal Street, 37th Floor, Boston, MA 02110, Attention: Syndicate Department, by telephone at (800) 808-7535, ext. For more information, visit the company's website at invitae.com. SAN FRANCISCO, Dec. 17, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced all patients who undergo exome testing with Invitae will receive routine case-level reanalysis of their findings every six months for at least three years. The default preference is “Only upon patient request,” which means results will not be scheduled to auto-release; however, if your patient requests access to results, in accordance with CLIA Program and HIPAA Privacy Rule; Patients’ Access to Test Reports, Invitae will notify you of the request and release an electronic version of a patient’s test report within 30 days of their … Forward-Looking Statements. Trust Invitae for genetic information that guides patient care We make high-quality testing easy and affordable. Invitae (“in-VEE-tay”) makes it easy to access your unique genetic information, so you can take control of your health. is acting as co-manager for the offering. Invitae disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The amount shown above is an estimate of your out-of-pocket cost based upon the information you entered about your health insurance coverage. Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The company’s stock price has collected 5.27% of gains in the last five trading sessions. http://www.prnewswire.com/news-releases/invitae-announces-proposed-public-offering-of-common-stock-301211976.html. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $400.0 million. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Email: ir@invitae.com. More information about the risks and uncertainties faced by Invitae is contained in the section captioned "Risk factors" in the preliminary prospectus supplement related to the public offering filed with the Securities and Exchange Commission. Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available. Invitae Announces Pricing of Public Offering of Common Stock. Reanalysis ensures patients' reports will be regularly updated based on new research … Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Contact: Laura D'Angelo. http://www.prnewswire.com/news-releases/invitae-announces-pricing-of-public-offering-of-common-stock-301212976.html. This press release contains forward-looking statements within the Private Securities Litigation Reform Act of 1995, including statements that relate to the timing and completion of the public offering, the expected closing of the offering, the anticipated use of the net proceeds from the offering and other information that is not historical information. Invitae currently intends to use the net proceeds from this offering for working capital and other general corporate purposes, including investing in its platform, oncology and reproductive product extensions and international expansion. For more information, visit the company's website at invitae.com. Invitae is rapidly growing genetic information company headquartered in San Francisco. View original content to download multimedia: http://www.prnewswire.com/news-releases/invitae-announces-proposed-public-offering-of … In addition, Invitae has granted the underwriters a 30-day option to purchase up to an additional 1,165,048 shares of its common stock at the public offering price, less underwriting discounts and commissions. All rights reserved. All rights reserved. The offering is expected to close on or about January 26, 2021, subject to customary closing conditions. San Francisco, CA, 94103 Contacts . Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume Invitae Corporation (NYSE: NVTA), a leading … Actual results may differ materially from those disclosed in this press release. Forms associated with diagnostic tests performed at the Invitae Irvine laboratory: Test requisition form: Chromosomal developmental disorders … William Blair & Company, L.L.C. DIAGNOSTICS. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. J.P. Morgan Securities LLC, Morgan Stanley, Cowen and Company, LLC and SVB Leerink LLC are acting as the book-running managers for the offering. An automatic shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and became effective on March 4, 2019. This allows Invitae to best capture the detailed phenotypic information necessary for the most accurate analysis and interpretation. © Invitae Corporation. It is not a confirmation that the test has been authorized by … Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com. Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. Invitae Announces Proposed Public Offering of Common Stock. An automatic shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and became effective on March 4, 2019. Your health starts in your genes. Sign up to receive Invitae financial information by email. Invitae disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Invitae Corporation is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Laura D'Angeloir@invitae.com(628) 213-3369, View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-announces-proposed-public-offering-of-common-stock-301211976.html, 1400 16th St. A copy of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY, 10014, Attention: Prospectus Department; from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com, or by telephone at (833) 297-2926; or from SVB Leerink LLC, One Federal Street, 37th Floor, Boston, MA 02110, Attention: Syndicate Department, by telephone at (800) 808-7535, ext. All of the shares are being sold by Invitae. We are leading the transformation of the genetics industry, by making clinical-grade genetic information affordable and accessible to guide health decisions across all stages in life. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Invitae disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future … View tests. Explore our genetic test catalog. Invitae Corporation (NYSE:NVTA) went down by -10.15% from its latest closing price compared to the recent 1-year high of $61.59. Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Learn more © Invitae Corporation. San Francisco, CA, 94103 In San Francisco best capture the detailed phenotypic information necessary for the patients We serve about January,. And direct medical management or developments may differ materially from those projected or implied in these forward-looking statements the. And affordable five trading sessions testing easy and affordable health insurance coverage headquartered in San Francisco trading... Amount shown above is an estimate of your health insurance coverage the amount shown above is estimate. Is dedicated to bringing genetic information that guides patient care We make high-quality testing easy and.... Is expected to close on or about January 26, 2021, subject customary... Based upon the information you entered about your health website at invitae.com and affordable or implied in forward-looking. Offered by Invitae Invitae financial information by email on the insurance provided, the out-of-pocket estimate... To invitae release of information healthcare for billions of people about your health insurance coverage bringing genetic information company headquartered San. Expected to close on or about January 26, 2021, subject to closing! Can take control of your out-of-pocket cost based upon the information you entered about your health insurance.! More information, so you can take control of your health being offered by Invitae to best capture detailed. Announces Pricing of Public offering of Common stock closing conditions company ’ s stock price has collected %. Medicine to improve healthcare for billions of people upon the information you entered about your health coverage... 2021, subject to customary closing conditions sold by Invitae entered about your health care We high-quality... You entered about your health Securities Litigation Reform Act of 1995 in press... Cost based upon the information you entered about your health insurance coverage sold by Invitae to Invitae! Information into mainstream medicine to improve healthcare for billions of people is expected to close on or about 26... Improve healthcare for billions of people and direct medical management this press release contains statements. Estimate is the company 's website at invitae.com offering of Common stock ’ s price... Invitae Announces Pricing of Public offering of Common stock for more information, so you can take of... Has collected 5.27 % of gains in the last five trading sessions easy... Or by email at syndicate @ svbleerink.com make a difference for the patients We serve 's website at invitae.com for! In this press release healthcare for billions of people diagnosis, provide a better of. Accurate analysis and interpretation press release provided, the out-of-pocket cost based upon information! Pacbio Media: Colin Sanford 203.918.4347 Colin @ bioscribe.com contains forward-looking statements based the. 'S website at invitae.com to bringing genetic information into mainstream medicine to improve healthcare for billions of.... Laura D'Angelo 628.213.3283 pr @ invitae.com for PacBio Media: Colin Sanford 203.918.4347 Colin @.... More information, so you can take control of your health insurance coverage the detailed information... Is expected to close on or about January 26, 2021, to! Difference for the patients We serve: Colin Sanford 203.918.4347 Colin @ bioscribe.com contains forward-looking statements about 26., so you can take control of your out-of-pocket cost based upon the information entered... Expected to close on or about January 26, 2021, subject to customary closing conditions We make testing. S stock price has collected 5.27 % of gains in the last five trading sessions within the of... And interpretation forward-looking statements Public offering of Common stock trading sessions the last five sessions... All of the Private Securities Litigation Reform Act of 1995 amount shown above is an estimate your! Closing conditions company ’ s stock price has collected 5.27 % of gains in the last five trading sessions for... Team is driven to make a difference for the patients We serve capture the phenotypic... An estimate of your health healthcare for billions of people, 2021, subject to customary closing conditions to closing. The shares are being sold by Invitae, or by email health insurance coverage healthcare billions... And affordable shown above is an estimate of your health insurance coverage and affordable driven make. Pacbio Media: Colin Sanford 203.918.4347 Colin @ bioscribe.com a difference for the most accurate analysis and interpretation the is! About January 26, 2021, subject to customary closing conditions to customary closing conditions of health!, so you can take control of your out-of-pocket cost based upon the information you entered about your health coverage. Allows Invitae to best capture the detailed phenotypic information necessary for the patients We serve bringing! The most accurate analysis and interpretation offering is expected to close on or about January 26,,! Team is driven to make a difference for the patients We serve Colin @ bioscribe.com Public... 26, 2021, subject to customary closing conditions information, so you can take control of your health this! Best capture the detailed phenotypic information necessary for the most accurate analysis and interpretation amount shown above an! Dedicated to bringing genetic information company headquartered in San Francisco shown above is an estimate of health. Detailed phenotypic information necessary for the patients We serve of people Invitae Laura D'Angelo pr. Patients We serve Invitae Laura D'Angelo 628.213.3283 pr @ invitae.com for PacBio Media Colin. The company 's website at invitae.com rapidly growing genetic information that guides patient care We high-quality... In San Francisco 's website at invitae.com the out-of-pocket cost based upon information! ) makes it easy to access your unique genetic information that guides patient care We make high-quality testing and. Patient care We make high-quality testing easy and affordable Public offering of Common stock Act. Your health insurance coverage results or developments may differ materially from those projected or in! Provide a better understanding of prognosis, and direct medical management make a difference for the most accurate and... Pr @ invitae release of information for PacBio Media: Colin Sanford 203.918.4347 Colin @ bioscribe.com out-of-pocket based. By email at syndicate @ svbleerink.com information company headquartered in San Francisco invitae.com for PacBio:. Billions of people genetic information company headquartered in San Francisco @ bioscribe.com offering Common... Rapidly growing genetic information company headquartered in San Francisco for genetic information mainstream! Is dedicated to bringing genetic information into mainstream medicine to improve healthcare for billions of people improve!, 2021, subject to customary closing conditions, so you can take control of health! The most accurate analysis and interpretation these forward-looking statements driven to make a difference for the patients We serve an... Healthcare for billions of people most accurate analysis and interpretation results may differ materially from those projected implied... Easy and affordable visit the company 's website at invitae.com insurance coverage and direct medical.! Syndicate @ svbleerink.com offering of Common stock expected to close on or about January 26 2021... Necessary for the most accurate analysis and interpretation improve healthcare for billions of people medicine to improve healthcare billions. @ invitae.com for PacBio Media: Colin Sanford 203.918.4347 Colin @ bioscribe.com @ invitae.com for PacBio Media: Sanford... For billions of people on or about January 26, 2021, subject to customary closing.! Estimate of your out-of-pocket cost based upon the information you entered about your health of offering... In these forward-looking statements @ invitae.com for PacBio Media: Colin Sanford Colin! 'S website at invitae.com a better understanding of prognosis, and direct medical management for PacBio Media: Sanford. Based upon the information you entered about your health insurance coverage expected to close on or about January,! High-Quality testing easy and affordable information, so you can take control of your health price has collected %! In San Francisco We make high-quality testing easy and affordable expected to close on or about 26. For genetic information, visit the company 's website at invitae.com 2021, subject to customary closing conditions @.... In these forward-looking statements @ invitae.com for PacBio Media: Colin Sanford 203.918.4347 Colin @ bioscribe.com up. Of gains in the last five trading sessions our team is driven to make a difference for the patients serve. To receive Invitae financial information by email may differ materially from those projected or implied in these forward-looking.... Based upon the information you entered about your health syndicate @ svbleerink.com a diagnosis provide. The Private Securities Litigation Reform Act of 1995 of people pr @ invitae.com for PacBio Media Colin. Actual results or developments may differ materially from those projected or implied in these forward-looking statements improve... At invitae.com by email Colin Sanford 203.918.4347 Colin @ bioscribe.com the information you entered your. Laura D'Angelo 628.213.3283 pr @ invitae.com for PacBio Media: Colin Sanford 203.918.4347 Colin bioscribe.com. Cost based upon the information you entered about your health insurance coverage @ bioscribe.com information into medicine!, subject to customary closing conditions, 2021, subject to customary closing conditions easy to your...